What does it take to turn a scientific discovery into a new cancer therapy? In a recent Tagesspiegel feature, CARtemis founders Uta Höpken and Armin Rehm from the Max Delbrück Center reflect on the long journey behind the development of a CXCR5-based cellular immunotherapy, from fundamental research to clinical translation. The article highlights how scientific persistence, close collaboration and sustained translational efforts over many years have helped advance the approach into clinical testing at Charité Berlin.